- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06143202
Feasibility of CGM Use in Hospitalized Youth
Feasibility of Continuous Glucose Monitor Use In Hospitalized Youth
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Youth and young adult patients admitted to the hospital for any reason, but require glucose monitoring during the hospitalization will be enrolled in this study. Participant diagnosis can include type 1 diabetes, type 2 diabetes, medication-induced diabetes, cystic fibrosis-related diabetes, or other causes of hyperglycemia that it has been determined by the hospital team requires frequent glucose monitoring, with or without insulin management.
Enrolled participants will wear a blinded continuous glucose monitor for up to 28 days (2 sensors) or until the end of their hospitalization. In addition, enrolled participants will complete a survey to assess their perspectives on the CGM wear experience and interest in future CGM use during hospitalizations. Nursing staff of the enrolled participant will also be invited to complete a survey regarding their perspectives of CGM use in the hospital setting.
Study Type
Enrollment (Estimated)
Contacts and Locations
Study Locations
-
-
California
-
San Francisco, California, United States, 94158
- University of California San Francisco
-
Stanford, California, United States, 94305
- Stanford University
-
-
Colorado
-
Aurora, Colorado, United States, 80045
- University Of Colorado, Barbara Davis Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Youth and young adult participants will be admitted to the hospital and have hyperglycemia resulting in an endocrine consult and requiring frequent glucose monitoring.
Nursing staff providing medical care for the youth and young adult participant will be invited to complete a survey on usability of the CGM in the hospital setting.
Description
Inclusion Criteria:
- Participants will be 2 to less than 26 years of age at the time of enrollment.
- Participants will have a diagnosis of type 1 diabetes, type 2 diabetes, diabetes/hyperglycemia due to an underlying condition (such as in cystic fibrosis, monogenic diabetes), or medication induced diabetes/hyperglycemia (such as steroid-induced hyperglycemia or PEG-asparaginase induced hyperglycemia) and would benefit clinically from close glucose monitoring during hospitalization due to fluctuations in blood glucose values.
- Participant is expected to be in the hospital for longer than 12 hours after study enrollment with a goal of 36 hours or more as determined by study investigator or trained staff.
- Participant is willing to wear the continuous glucose monitor for the duration of the hospital admission or the lifespan of a continuous glucose monitor (7-14 days).
Exclusion Criteria:
- Has had a history of a significant skin reaction to the adhesives of a continuous glucose monitor in the past or concerns that one may occur due to underlying skin conditions (ie severe eczema, uncontrolled psoriasis, etc).
- Planned MRI or surgery during the study device use (can be enrolled pre or post procedure if sufficient time for sensor wear as determined by investigator [i.e. 24-48 before planned procedure]).
- Admission to inpatient psychiatry.
- Pregnancy.
- Currently using hydroxyurea.
- A condition that the investigator determines would prevent the patient from participation.
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
|---|---|
|
You and young adult patients with hyperglycemia
Any youth and young adult patient admitted to the hospital and requiring an endocrine consult for frequent glucose monitoring and hyperglycemia management
|
Youth and young adult participants will wear a blinded Freestyle Libre 3 CGM.
Data will not be available, and therefore the device will not be used to modify medical management.
|
|
Nursing staff
Nursing staff providing medical care for youth and young adult patients enrolled in the study.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Retrospective glycemic CGM and point of care comparison
Time Frame: Duration of study, approximately 1 year from study start
|
Glycemic data related to time in range, time hypoglycemic, time hyperglycemic and the time of first onset of hypoglycemia and hyperglycemia will be obtained by both CGM and point of care glucose values.
|
Duration of study, approximately 1 year from study start
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Nursing staff perspectives of CGM use in the hospital
Time Frame: Duration of study, approximately to 1 year from study start
|
Surveys will be provided to the nursing staff associated with an enrolled patient participant to obtain qualitative perspectives on the usability of CGMs in the hospital setting
|
Duration of study, approximately to 1 year from study start
|
|
Patient/Family perspectives of CGM use in the hospital
Time Frame: Duration of study, approximately 1 year from study start
|
Surveys will be completed by patients/family to evaluate their experience with sensor wear in the hospital, sensor insertion, and goals for glycemic monitoring while in the hospital.
|
Duration of study, approximately 1 year from study start
|
|
Feasibility of CGM use through assessment of discontinuation and data loss
Time Frame: Duration of study, approximately 1 year from study start
|
Identify the frequency and causes of sensor discontinuation as well as information on sensor data loss.
|
Duration of study, approximately 1 year from study start
|
|
Health economics data
Time Frame: Duration of study, approximately 1 year from study start
|
Pilot analysis of health economics data from costs related to glycemic monitoring during the hospitalization.
|
Duration of study, approximately 1 year from study start
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 23-1051
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hyperglycemia
-
Mayo ClinicCompletedHospital Hyperglycemia | Post-transplant HyperglycemiaUnited States
-
Zealand University HospitalNot yet recruitingStress Hyperglycemia | Postoperative Hyperglycemia
-
University of CopenhagenUnknownSurgery--Complications | Hyperglycemia Stress | Hyperglycemia Steroid-inducedDenmark
-
University of LeedsCompletedEffect of Food on Postprandial HyperglycemiaUnited Kingdom
-
Zealand University HospitalRecruitingAnesthesia | Surgical Procedure, Unspecified | Hyperglycemia Stress | Continuous Glucose Monitoring | Hyperglycemia Steroid-inducedDenmark
-
University Hospital, Gentofte, CopenhagenCompletedPancreatectomy; HyperglycemiaDenmark
-
Emory UniversityNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); National...TerminatedHyperglycemia StressUnited States
-
Loughborough UniversityUniversity of BedfordshireCompletedPostprandial HyperglycemiaUnited Kingdom
-
Centre Hospitalier Universitaire de BesanconEli Lilly and Company; AstraZenecaCompleted
Clinical Trials on Freestyle Libre 3 Continuous Glucose Monitor
-
Foundation for Innovative New Diagnostics, SwitzerlandThe Leona M. and Harry B. Helmsley Charitable Trust; Kenya Diabetes Management...Not yet recruiting
-
University of California, San FranciscoActive, not recruitingType 2 DiabetesUnited States
-
NYU Langone HealthActive, not recruitingType 2 Diabetes | Mild Cognitive ImpairmentUnited States
-
HealthPartners InstituteCompletedMetastatic Breast CancerUnited States
-
University of Colorado, DenverCompletedHematopoietic Stem Cell TransplantationUnited States
-
Imperial College LondonCompletedType1diabetes | Type 1 Diabetes Mellitus With Hypoglycemia | Impaired Awareness of Hypoglycemia
-
Mayo ClinicRecruitingHyperglycemia | Hypoglycemia | Type 2 Diabetes MellitusUnited States
-
Vanderbilt University Medical CenterRecruitingHyperglycemia | Type 2 Diabetes Mellitus (T2DM) | Type 1 Diabetes Mellitus (T1DM)United States
-
University of the PacificRecruitingType 1 Diabetes | Type 2 DiabetesUnited States